PD-1抗体联合mFOLFOX6肝动脉灌注化疗对中晚期原发性肝癌患者肿瘤标志物水平及生存质量的影响  

The Effect of PD-1 Antibody Combined with mFOLFOX6 Hepatic Arterial Infusion Chemotherapy on Tumor Marker Levels and Quality of Life in Patients with Advanced Primary Liver Cancer

作　　者：朱大艳 刘延浩 朱桂丽 ZHU Dayan;LIU Yanhao;ZHU Guili(Kaifeng Central Hospital,Kaifeng,475000)

机构地区：[1]河南省开封市中心医院,475000

出　　处：《实用癌症杂志》2025年第3期492-495,共4页The Practical Journal of Cancer

摘　　要：目的 观察PD-1抗体联合mFOLFOX6肝动脉灌注化疗对中晚期原发性肝癌(PHC)患者肿瘤标志物水平及生存质量的影响,探索PD-1抗体联合mFOLFOX6方案用于中晚期PHC治疗的价值。方法 纳入中晚期PHC患者62例,随机分为试验组和对照组,试验组采用卡瑞利珠单抗联合mFOLFOX6方案治疗,对照组采用mFOLFOX6方案治疗,比较2组患者治疗后1月、3月甲胎蛋白(AFP)、糖类抗原199(CA199)、糖链抗原50(CA50)水平及生存质量评分。结果 2组患者一般基线资料及治疗前AFP、CA199、CA50水平及生存质量评分差异无统计学意义;治疗后1月试验组AFP、CA199、CA50低于对照组,生存质量评分高于对照组,差异有统计学意义(P均<0.05);治疗后3月试验组AFP、CA199、CA50低于对照组,生存质量评分高于对照组,差异有统计学意义(P均<0.05)。结论 PD-1抗体联合mFOLFOX6肝动脉灌注化疗可显著降低患者肿瘤标志物水平,提高患者生存质量,治疗效果显著优于单独采用mFOLFOX6方案治疗。Objective To observe the effect of PD-1 antibody combined with mFOLFOX6 hepatic arterial infusion chemotherapy on tumor marker levels and quality of life in patients with advanced primary liver cancer(PHC),and explore the value of PD-1 antibody combined with mFOLFOX6 regimen in the treatment of advanced PHC.Methods 62 patients with advanced stage PHC were randomly divided into an experimental group and a control group.The experimental group was treated with the combination of Carilizumab and mFOLFOX6 regimen,while the control group was treated with mFOLFOX6 regimen.The levels of alpha fetoprotein(AFP),carbohydrate antigen 199(CA199),carbohydrate antigen 50(CA50),and quality of life scores were compared between the 2 groups at 1 and 3 months after treatment.Results There was no statistically significant difference in baseline data,pre-treatment AFP,CA199,CA50 levels,and quality of life scores between the two groups of patients;After one month of treatment,the experimental group had lower levels of AFP,CA199,and CA50 than the control group,and higher quality of life scores than the control group,with statistically significant differences(P<0.05);After 3 months of treatment,the experimental group had lower levels of AFP,CA199,and CA50 than the control group,and higher quality of life scores than the control group,with statistically significant differences(P<0.05).Conclusion PD-1 antibody combined with mFOLFOX6 hepatic arterial infusion chemotherapy can significantly reduce the levels of tumor markers in patients,improve their quality of life,and have significantly better therapeutic effects than mFOLFOX6 alone.

关 键 词：原发性肝癌 PD-1抗体 MFOLFOX6 

分 类 号：R735.7[医药卫生—肿瘤]